Fotemustine and dacarbazine plus recombinant interferon alpha2a in the treatment of advanced melanoma

P. Comelia, A. Daponte, R. Casaretti, F. Ionna, F. Fiore, F. Presutti, G. Frasci, F. Caponigro, A. Gravina, A. P. Parziale, N. Mozzillo, G. Comelia

Research output: Contribution to journalArticlepeer-review


Forty-three consecutive patients with advanced melanoma not previously treated with cytotoxic drugs (22 of them had already received adjuvant recombinant interferon alpha2a (rIFNα2a)) were given a combination of intravenous (i.v.) fotemustine (FM), 100 mg/m2 on day 1, and dacarbazine (DTIC), 250 mg/m2 i.v. on days 2-5, every 3 weeks. rIFNα2a was administered at the dosage of 3 MIU subcutaneously 3 times a week until progression. Four complete and 13 partial responses were registered, for an overall response rate of 40% (95% CI, 25-56%). Activity of this regimen was similar in patients with mainly Visceral (10/22, 45%) or soft tissue (6/13, 46%) involvement. The median duration of responses was 24 weeks. Median survival time was 40 weeks, with a 13% 2 year survival rate. Neutropenia and thrombocytopenia affected 67% and 51% of patients, but were of WHO grade 4 in only 2% and 5% of them, respectively. Side-effects attributable to rIFNα2a were mild and manageable. In conclusion, the combination of FM + DTIC and rIFNα2a seemed well tolerated and relatively active in patients with advanced melanoma. However, the role of rIFNα2a in affecting the long-term outcome of patients is still questionable.

Original languageEnglish
Pages (from-to)1326-1329
Number of pages4
JournalEuropean Journal of Cancer
Issue number8
Publication statusPublished - Jul 1997


  • Dacarbazine
  • Fotemustine
  • Melanoma
  • rIFNα2a

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Fotemustine and dacarbazine plus recombinant interferon alpha2a in the treatment of advanced melanoma'. Together they form a unique fingerprint.

Cite this